Next Phase Newsletter

A European Venture Capital firm is looking to invest exclusively invests in early stage life science companies. The firm makes seed and early stage investments typically in the Series A round and can allocate €1-10M initially and an additional €10-15M in a follow-on investment per company. The firm typically co-invests with other institutional investors for larger investments. The firm is actively seeking opportunities throughout United States and Europe.

The firm is currently looking for biotech therapeutics, medical devices, and industrial biotech. For therapeutics, the firm invests in small molecule and biologics as well as cell and gene therapy. The firm is open to all indications as well as orphan indications. The firm will consider products as early as 24-month from IND through to Phase II. For medical devices, the firm seeks paradigm-shifting technologies that can reach a human proof-of-concept stage in a relatively short period of time.

The firm prefers to lead or co-lead an investment and generally require a board seat in its portfolio companies.

A family office based in the north eastern United States is dedicated to accelerating the translation of new and innovative programs in the CV and stroke areas. The firm makes equity and convertible note investments of approximately $1 million into companies that are targeting cardiovascular and neurovascular diseases. The firm invests in privately held companies at both the seed and venture stage and is currently invests in 4-5 companies per year. The firm operates under an evergreen structure and is constantly seeking new investment opportunities. While the firm will consider investments around the globe, the firm is keen to add companies based in Europe to its portfolio. The firm is currently looking for companies in both the Biotech Therapeutic & Diagnostics and Medtech sectors. The firm’s focus is on companies developing technologies for cardiovascular, neurovascular and metabolic diseases (diabetes, dyslipidemia and obesity). The firm looks to invest in companies where the investment will help move the company to an inflection point necessary for the next and larger investment round.  The firm is only willing to allocate to companies who have a clear impact on patient therapy and/or standard of care, an adequate level of IP protection, well-defined use of proceeds with quantifiable and achievable milestones, and a clear understanding of the next round of fundraising needs including how much and likely sources.

An angel network based out of the North Eastern United States looks to make equity investments in early-stage and selectively seed stage life science companies ranging from $.5 – $1.5 million. The firm is also open to syndication on larger deals will consider opportunities throughout the United States and Canada. The firm plans to allocate to 10 new companies over the next year.

The group is open to sectors in the life science space including therapeutics, diagnostics and medical devices. The firm is generally opportunistic in terms of technology type, indication and is open to both small molecules and biologics. The firm is comfortable in investing in series A, B, C, or D rounds and is willing to invest in technologies that are pre-clinical or in early clinical trials.

The is most interested in investing in companies with experienced management teams though they also consider spinouts from universities in certain situations. The firm looks to invest in privately held companies and generally takes a seat on the company’s board.

A venture capital company based on the West Coast of the United States is currently making investments out of its second fund. The firm looks to make seed and series A investments ranging from $50,000 to $5 million in the initial round with additional capital reserved for follow on financing pending the company has reached positive milestones. The firm is actively seeking new investments and is looking globally for opportunities.

The firm is currently looking for companies in sectors of Healthcare IT, Big Data Analytics, Bioinformatics and Genomics with special interest for applications of personalized medicine and predictive diagnostics. Though the firm has made medical device investments in the past, the firm is generally shifting away from devices that enable treatment and is focusing on software and software enabled devices that are used to generate and/or analyze biological data. The firm is especially interested in scalable platforms that have the potential for use in more than one indication or aspect of healthcare. The firm is generally open in terms of indication though they have invested in the past with companies working with chronic disease such as cancer as well as behavioral health and pain.

The firm is looking for privately held companies with experienced management teams. The firm looks to help the companies pivot and develop their technologies adding strategic value in addition to just capital.

A private investment vehicle for a successful entrepreneur that was founded in 2012 and based in Western Europe is currently looking globally for therapeutics. The firm looks to make equity investments into therapeutics companies of up to $5 million initially for approximately 30% equity with additional capital reserved for follow-on rounds. The firm has no set number of allocations that it plans to make but is actively seeking new investments. The firm is looking for companies located around the globe.

The firm is looking for companies in the Therapeutics space developing small molecules or biologics. While the firm prefers companies in clinical trials they are also open to considering preclinical companies with strong animal data. The firm has special interest in diabetes and generally stays away from neurology and cancer, but is open to review all indications and therapeutic types.

The firm evaluates management on a case by case basis and prefers to work with management teams that have domain expertise and experience in their indication area. The firm generally looks to take a board seat following investment.

The venture investment arm of a Large Pharmaceutical Company with offices throughout the United States and Europe is looking to invest in 5-10 firms over the course of the next year. The firm covers a broad range of investments from seed through Series A, B, and C rounds.  The firm typically commits ~$25m over the life of an investment.

The firm invests in promising companies developing breakthrough innovations for high unmet need clinical problems. The firm broadly covers the healthcare market with investments across therapeutics, devices, diagnostics and healthcare services.  The firm will consider opportunities ranging from discovery concept through Phase II.  The fund is highly focused on technology innovation and will invest across all therapeutic areas and technology modalities.

The firm invests in pre-revenue, early stage companies, and prefers to invest in management teams with a foundation of expertise in their field.  In cases where the firm invests at the seed stage, the fund may be a very hands-on investor to help build the company, but is typically less hands-on when investing in mature companies.  As an early-stage investor the firm typically invests in privately-held companies, but also has the capability to invest in public companies and has had several portfolio companies go public subsequent to investment

A private equity firm Based in the Midwestern United States has invested over $800 million over its lifetime and is currently making investments out of its 12th $100 million fund. The firm is looking to make growth equity allocations of around $3-$5 million initially and up to $10 million over the lifetime of the investment. The firm will consider companies around the globe and is looking to make 4-5 investments over the next 12 months.

The firm is most interested in innovative medical technology companies that recently received FDA approval for their product. The firm has experience in medical devices, delivery devices, implantable devices, and reusable instruments so companies within those subsectors would be ideal however other medical technologies may also be considered. The firm also has interest in the Biotech R&D services sector within subsectors of CRO’s, diagnostic instrumentation and healthcare IT.

The firm is looking to invest in a company with approximately $5 million in yearly revenue with a strong management team. The firm will consider small public or private companies for investment and looks to acquire an active position on the company’s advisory board.